New Ray Medicine International Holding Limited’s monthly return for the period ended 31 July 2026 shows a stable share structure, with no changes to authorised, issued or treasury shares.

Authorised/Registered Capital • Authorised share capital remained at 15.00 billion ordinary shares with a par value of HKD 0.01, translating to HKD 150.00 million in authorised capital.

Issued Shares and Public Float • Issued shares held steady at 200.62 million, and the company continued to hold zero treasury shares. • The board confirmed compliance with the Main Board’s minimum 25 % public-float requirement.

Share Option Scheme • Outstanding options under the Share Option Scheme adopted on 25 October 2013 totalled 12.82 million, unchanged during the month. • No options were exercised, no new shares were issued, and no funds were raised. • If fully exercised, the outstanding options would represent potential dilution of approximately 6.39 % of the current issued share base.

Other Instruments • The company reported no warrants, convertibles, or other agreements or arrangements to issue shares during the period.

Overall, the July 2026 filing confirms a month of zero equity movements for New Ray Medicine, preserving both capital structure and public-float compliance.